Table 2.

Conventional prognostic factors in stage III non-small cell lung cancer: medical series.

Study	Year	ISS	Stage	N patients	Treatment	Significant factors in multivariate analysis
Coen et al. [1995]	1995	4th	III	239	RT+/−CT	RT dose, pleural effusion
Jeremic and Shibamoto [1995]	1995	?	III	169	CRT	Age, stage, gender, PS, weight loss
Furuse et al. [1999]	1999	4th	III	320	CRT	PS, concomitant CRT
Martins and Pereira [1999]	1999	?	III	796	?	PS, weight loss, superior vena cava syndrome, surgery, CT, RT
Sculier et al. [1999b]	1999	4th	III	462	CT versus CRT	PS, age, stage, neutrophils, platelets, response to CT
Sculier et al. [1999a]	1999	4th	III	115	CT → CT or RT	PS
Suzuki et al. [1999b]	1999	5th	pI-IV	836	?	IIIA: T size
						IIIB: pN2-3
Langendijk et al. [2000a]	2000	4th	III	198	RT	PS, weight loss, N, QOL
Firat et al. [2002]	2002	4th	III	112	RT	PS, co-morbidity
Brooks et al. [2003]	2003	?	III	59	CRT	p53, hMSH2
Sculier et al. [2004]	2004	5th	III	328	CRT	PS, stage, haemoglobin, bilirubin
Socinski et al. [2004]	2004	?	Dry III	694	RT, CRT	Haemoglobin, PS, RT vs RT/CT
Stinchcombe et al. [2006]	2006	?	III	102	CRT	Tumour volume, PS, stage
Basaki et al. [2006]	2006	?	III	71	RT (+/− CT)	Tumour volume, TTV
Ademuyiwa et al. [2007]	2007	5th?	III	203	?	Age, gender, ethnicity, BMI, PS, FEV1, smoking, haemoglobin, SUV, stage
Vokes et al. [2007]	2007	5th?	III	366	CRT	PS, age, weight loss
Nakamura et al. [2008]	2008	5th	III	102	RT+/−CT	Tumour site
Sculier et al. [2008]	2008	7th	IIIA	2048	?	Age, gender, histology, PS
Garrido et al. [2009]	2009	5th	III	139	CRT	Concurrent CRT

BMI, body mass index; PS, performance status; FEV1, forced expiratory volume in 1 second; SUV, standardized uptake value; TTV, target treatment volume; RT, radiotherapy; CT, chemotherapy; CRT, radiochemotherapy; N, node; QOL, quality of life; T, tumour.